202 related articles for article (PubMed ID: 16038981)
21. Government regulations and the use of drugs.
Hafkenschiel JH
Calif Med; 1967 Aug; 107(2):159-63. PubMed ID: 4862066
[TBL] [Abstract][Full Text] [Related]
22. Organizational and client determinants of cost in outpatient substance abuse treatment.
Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
[TBL] [Abstract][Full Text] [Related]
23. Long-term adjunctive quetiapine may reduce substance use--a preliminary retrospective study.
Sattar SP; Schultz SK; Arndt S; Soundy T; Petty F
S D Med; 2007 Nov; 60(11):437, 439-41, 443 passim. PubMed ID: 18196687
[TBL] [Abstract][Full Text] [Related]
24. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?
Hewitt NJ; de Kanter R; LeCluyse E
Chem Biol Interact; 2007 May; 168(1):51-65. PubMed ID: 17239835
[TBL] [Abstract][Full Text] [Related]
25. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
[TBL] [Abstract][Full Text] [Related]
26. A Pressing Need for Pharmacotherapy Development to Treat Drug Addiction: An Editorial from a Legal Perspective.
Andraka-Christou B
Int Rev Neurobiol; 2016; 126():15-38. PubMed ID: 27055610
[TBL] [Abstract][Full Text] [Related]
27. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
[TBL] [Abstract][Full Text] [Related]
28. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
29. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
30. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
Mathis LL; Iyasu S
Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
[TBL] [Abstract][Full Text] [Related]
31. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs.
Schuster CR
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S8-14. PubMed ID: 16483729
[TBL] [Abstract][Full Text] [Related]
32. Benefit adequacy among elderly Social Security retired-worker beneficiaries and the SSI federal benefit rate.
Rupp K; Strand A; Davies P; Sears J
Soc Secur Bull; 2007; 67(3):29-51. PubMed ID: 18605217
[TBL] [Abstract][Full Text] [Related]
33. Effective executive management in the pharmaceutical industry.
Tran H; Kleiner BH
J Health Care Finance; 2005; 32(1):8-15. PubMed ID: 18972973
[TBL] [Abstract][Full Text] [Related]
34. Development of medications for alcohol use disorders: recent advances and ongoing challenges.
Litten RZ; Fertig J; Mattson M; Egli M
Expert Opin Emerg Drugs; 2005 May; 10(2):323-43. PubMed ID: 15934870
[TBL] [Abstract][Full Text] [Related]
35. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
Chodock R; Yolkut D; Connolly DR
Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
[TBL] [Abstract][Full Text] [Related]
36. Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs.
Saxon AJ; McCarty D
Pharmacol Ther; 2005 Oct; 108(1):119-28. PubMed ID: 16055196
[TBL] [Abstract][Full Text] [Related]
37. Development of opioid formulations with limited diversion and abuse potential.
Fudala PJ; Johnson RE
Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S40-7. PubMed ID: 16564141
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
Yeom HS; Shepard DS
J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
[TBL] [Abstract][Full Text] [Related]
39. [Are children getting the right drugs?].
Bratlid D
Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857
[TBL] [Abstract][Full Text] [Related]
40. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
